ALNY analyst estimates
Alnylam (ALNY) analyst ratings, the average price target and its range, and every firm's latest call.
ALNY analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | Raymond James | Raymond James Downgrades Alnylam Pharmaceuticals (ALNY) to Outperform | $315.00 |
| Oct 30, 2026 | Wells Fargo | Alnylam Pharmaceuticals (ALNY) PT Lowered to $287 at BofA Securities | $287.00 |
| Oct 30, 2026 | BMO Capital | Alnylam Pharmaceuticals (ALNY) PT Lowered to $290 at BMO Capital | $290.00 |
| Oct 30, 2026 | UBS | Alnylam Pharmaceuticals (ALNY) PT Lowered to $329 at UBS | $329.00 |
| Oct 29, 2026 | Stifel Nicolaus | Stifel Downgrades Alnylam Pharmaceuticals (ALNY) to Hold | $225.00 |
| Oct 15, 2026 | UBS | Alnylam assumed with a Buy at UBS | $354.00 |
| Oct 14, 2026 | Wells Fargo | Alnylam price target lowered to $253 from $256 at Wells Fargo | $253.00 |
| Oct 8, 2026 | RBC Capital | Alnylam price target lowered to $345 from $350 at RBC Capital | $345.00 |
| Sep 8, 2026 | Jefferies | Alnylam price target raised to $260 from $230 at Jefferies | $260.00 |
| Aug 28, 2026 | Jefferies | Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data | $230.00 |
| Aug 25, 2026 | Bernstein | Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) | $376.00 |
| Aug 18, 2026 | BMO Capital | Alnylam initiated with an Outperform at BMO Capital | $318.00 |
| Aug 14, 2026 | Wells Fargo | Alnylam price target lowered to $256 from $316 at Wells Fargo | $256.00 |
| Aug 4, 2026 | Truist Financial | Alnylam price target lowered to $315 from $410 at Truist | $315.00 |
| Aug 4, 2026 | H.C. Wainwright | Alnylam price target lowered to $455 from $485 at H.C. Wainwright | $455.00 |
- 23 firms rate ALNY: 18 buy, 5 hold, 0 sell.
- The average price target is $319.70 from 10 analysts, from $225.00 to $455.00.
Updated 2026-11-02 18:26 UTC